SLS · SELLAS Life Sciences Group, Inc.
$15.46
+2.06 (+15.37%)
At close · Aug 21
Going-concern doubt
— cleared Aug 11, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents will be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements”View the 10-Q filed Aug 11, 2026
Market Cap
$2.69B
Shares
201.95M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-03 | — | $150,000,000 | — | — | 10-Q , filed 2026-08-11 |
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2010-12-31 | $3,849,000 | 10-K, filed 2012-03-28 |
Key facts
CIK
1390478
CUSIP
81642T209
13F (30d)
184 filings
182 filers
Visit website
Investor relations